Resolution Medical

Resolution Medical operates as an integrated medical-device development and manufacturing partner rather than as a single-product device company. Its offering spans early concept work, engineering, biosimulation, new-product introduction, process validation, component fabrication, cleanroom assembly, sterile packaging, and commercialization support. The company focuses on technically demanding categories including complex catheter systems, delivery systems, implants, active implants, interventional devices, and neuromodulation products. Its more than 70,000 square feet of facilities and 36,000 square feet of Class 7 and Class 8 clean rooms provide a manufacturing footprint that supports both development and production. LifeTec BioSim capabilities add realistic cardiovascular device delivery and deployment testing. Resolution Medical’s acquisition by Resonetics in 2026 materially changes its market context by connecting its capabilities to a larger integrated-device platform. Its clearest differentiator is the combination of engineering, simulation, specialized manufacturing, and clinical-development support under one operating model.

Resolution Medical’s trajectory shows expansion from a medical-device development specialist into a broader integrated design, testing, and manufacturing platform. Founded in 2012, the company added LifeTec Group through an acquisition announced on Jun 9, 2022, strengthening its biosimulation and cardiovascular testing capabilities. Peter Herman was appointed chief executive officer on Mar 6, 2023, marking a leadership change during the company’s scale-up phase. A BIRD Foundation grant announced on Oct 10, 2025 provided additional support for research and development, although the company-specific amount is undisclosed. The largest inflection point came in 2026: Resonetics announced its acquisition of Resolution Medical on Jan 27, 2026 and completed the transaction on Mar 23, 2026. That combination broadens access to integrated capabilities in interventional and neuromodulation markets. The company’s stated services now cover the full path from concept through first-in-human studies, process development, and low- to high-volume manufacturing.